 Kezar Life Sciences, Inc. NASDAQ: KZR shares are soaring Tuesday following a positive clinical readout. What Happened: California-based Kezar announced positive interim results from the Phase 2 portion of the MISSION clinical study evaluating KZR-616 in patients with lupus nephritis. 